Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropanicant in Moderate to Severe Major Depressive Disorder
NCT06126497Phase 2Completed
- Sponsor
- Suven Life Sciences
- Start
- Feb 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Ropanicant in major depressive disorder (MDD) (3 arms), sponsored by Suven Life Sciences. Primary endpoint: Treatment-Emergent Adverse Events at 3 weeks. Started Feb 2024; status: completed.
02
Drugs
Ropanicant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06126497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126497.